NCT00667121 - Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 16, 2011

Primary Completion Date

May 12, 2014

Study Completion Date

May 27, 2014

Conditions

Breast CancerDepressionHot FlashesPsychosocial Effects of Cancer and Its Treatment

Interventions

DRUG

citalopram hydrobromide

DRUG

escitalopram oxalate

DRUG

gabapentin

DRUG

sertraline hydrochloride

DRUG

tamoxifen citrate

DRUG

venlafaxine

GENETIC

molecular genetic technique

OTHER

high performance liquid chromatography

OTHER

laboratory biomarker analysis

OTHER

pharmacological study

PROCEDURE

adjuvant therapy

Trial Locations (6)

Virginia Cancer Specialists PC-Arlington, Arlington

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

Mayo Clinic, Rochester

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

University of Michigan Comprehensive Cancer Center, Ann Arbor